Biological Information
Background Information:
Two high affinity VEGF receptors, Flt-1 (VEGFR-1, activated by placental growth factor PlGF) and KDR (Kinase insert domain receptor, Flk-1/VEGFR2, activated by VEGF), have been identified. These receptors can be divided into three structural regions: seven extracellular Ig-like domains that contain the growth factor binding sites, a single polypeptide chain hydrophobic trans-membrane sequence, and intracellular cytoplasmic domains that confer the tyrosine kinase activity required for signal transduction. VEGF-B and VEGF-D homologues bind with high affinity to FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor/vascular permeability factor receptor).
PathHunter Receptor Tyrosine Kinase (RTK) Activity cell lines are engineered to express a fusion of the intracellular catalytic domain from the target RTK and the extracellular ligand binding domain of EGFR. This fusion protein is tagged with ProLink™ (PK). The cells co-express an Enzyme Acceptor (EA) tagged SH2 domain. Ligand induced cross-phosphorylation of the PK-tagged fusion protein leads to SH2-EA recruitment, forcing complementation of the two β-galactosidase enzyme fragments (EA and PK). The resulting functional enzyme hydrolyzes substrate to generate a chemiluminescent signal.
Family:
Kinase
Sub Family:
RTK
Class:
Protein Tyrosine
Protein Name:
KDR (VEGFR2)
Uniprot Number:
P35968
Protein Aliases:
vascular endothelial growth factor receptor 2|fetal liver kinase 1
Gene Name:
KDR
Gene ID:
3791
Gene Aliases:
FLK1|VEGFR|VEGFR2|CD309
Accession Number:
NM_002253
Organism:
Human
Cell Type:
U2OS
Assay Information
Assay Type:
Functional
Assay Sub Type:
Cell Based
Functional Mode:
Antagonist
Testing Information
Control Inhibitor:
Foretinib
Test Concentration / Dose:
Eurofins will provide IC/EC50 calculation if 10 concentrations are selected
Test Sample Requirements:
40uL of a 1000X stock for the first assay and 2uL for each additional assay (assay = 1 target, 1 readout, 1 mode)
Minimum Order Quantity:
20
Turnaround Time
Standard:
15 Business Days
Clinical Relevance
Adverse / Beneficial Action:
Tyrosine kinase KDR inhibitors may be useful in the treatment of tumor angiogenesis.
Additional Information
Brand:
LeadHunter
Testing Location:
USA - Fremont, CA